Cargando…
Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections
Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis throughout the world. Most infections are acute but they can become chronic in immunocompromised patients, such as solid organ transplant patients, patients with hematologic malignancy undergoing chemotherapy and those with a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073673/ https://www.ncbi.nlm.nih.gov/pubmed/31991629 http://dx.doi.org/10.3390/jcm9020331 |
_version_ | 1783506672508993536 |
---|---|
author | Lhomme, Sébastien Marion, Olivier Abravanel, Florence Izopet, Jacques Kamar, Nassim |
author_facet | Lhomme, Sébastien Marion, Olivier Abravanel, Florence Izopet, Jacques Kamar, Nassim |
author_sort | Lhomme, Sébastien |
collection | PubMed |
description | Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis throughout the world. Most infections are acute but they can become chronic in immunocompromised patients, such as solid organ transplant patients, patients with hematologic malignancy undergoing chemotherapy and those with a human immunodeficiency virus (HIV) infection. Extra-hepatic manifestations, especially neurological and renal diseases, have also been described. To date, four main genotypes of HEV (HEV1-4) were described. HEV1 and HEV2 only infect humans, while HEV3 and HEV4 can infect both humans and animals, like pigs, wild boar, deer and rabbits. The real epidemiology of HEV has been underestimated because most infections are asymptomatic. This review focuses on the recent advances in our understanding of the pathophysiology of acute HEV infections, including severe hepatitis in patients with pre-existing liver disease and pregnant women. It also examines the mechanisms leading to chronic infection in immunocompromised patients and extra-hepatic manifestations. Acute infections are usually self-limiting and do not require antiviral treatment. Conversely, a chronic HEV infection can be cleared by decreasing the dose of immunosuppressive drugs or by treating with ribavirin for 3 months. Nevertheless, new drugs are needed for those cases in which ribavirin treatment fails. |
format | Online Article Text |
id | pubmed-7073673 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70736732020-03-19 Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections Lhomme, Sébastien Marion, Olivier Abravanel, Florence Izopet, Jacques Kamar, Nassim J Clin Med Review Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis throughout the world. Most infections are acute but they can become chronic in immunocompromised patients, such as solid organ transplant patients, patients with hematologic malignancy undergoing chemotherapy and those with a human immunodeficiency virus (HIV) infection. Extra-hepatic manifestations, especially neurological and renal diseases, have also been described. To date, four main genotypes of HEV (HEV1-4) were described. HEV1 and HEV2 only infect humans, while HEV3 and HEV4 can infect both humans and animals, like pigs, wild boar, deer and rabbits. The real epidemiology of HEV has been underestimated because most infections are asymptomatic. This review focuses on the recent advances in our understanding of the pathophysiology of acute HEV infections, including severe hepatitis in patients with pre-existing liver disease and pregnant women. It also examines the mechanisms leading to chronic infection in immunocompromised patients and extra-hepatic manifestations. Acute infections are usually self-limiting and do not require antiviral treatment. Conversely, a chronic HEV infection can be cleared by decreasing the dose of immunosuppressive drugs or by treating with ribavirin for 3 months. Nevertheless, new drugs are needed for those cases in which ribavirin treatment fails. MDPI 2020-01-24 /pmc/articles/PMC7073673/ /pubmed/31991629 http://dx.doi.org/10.3390/jcm9020331 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lhomme, Sébastien Marion, Olivier Abravanel, Florence Izopet, Jacques Kamar, Nassim Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections |
title | Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections |
title_full | Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections |
title_fullStr | Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections |
title_full_unstemmed | Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections |
title_short | Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections |
title_sort | clinical manifestations, pathogenesis and treatment of hepatitis e virus infections |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073673/ https://www.ncbi.nlm.nih.gov/pubmed/31991629 http://dx.doi.org/10.3390/jcm9020331 |
work_keys_str_mv | AT lhommesebastien clinicalmanifestationspathogenesisandtreatmentofhepatitisevirusinfections AT marionolivier clinicalmanifestationspathogenesisandtreatmentofhepatitisevirusinfections AT abravanelflorence clinicalmanifestationspathogenesisandtreatmentofhepatitisevirusinfections AT izopetjacques clinicalmanifestationspathogenesisandtreatmentofhepatitisevirusinfections AT kamarnassim clinicalmanifestationspathogenesisandtreatmentofhepatitisevirusinfections |